Huaren Pharmaceutical Co Ltd (SHE:300110) — Market Cap & Net Worth
Market Cap & Net Worth: Huaren Pharmaceutical Co Ltd (300110)
Huaren Pharmaceutical Co Ltd (SHE:300110) has a market capitalization of $544.93 Million (CN¥3.72 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #12080 globally and #3723 in its home market, demonstrating a 2.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Huaren Pharmaceutical Co Ltd's stock price CN¥3.15 by its total outstanding shares 1182212982 (1.18 Billion). Analyse how efficiently does Huaren Pharmaceutical Co Ltd generate cash to see how efficiently the company converts income to cash.
Huaren Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Huaren Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.36 Billion to $544.93 Million (-5.91% CAGR).
Huaren Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Huaren Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.45x
Huaren Pharmaceutical Co Ltd's market cap is 0.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.36 Billion | $1.11 Billion | $22.94 Million | 1.23x | 59.28x |
| 2016 | $1.50 Billion | $1.25 Billion | $23.95 Million | 1.20x | 62.61x |
| 2017 | $2.02 Billion | $1.31 Billion | $37.54 Million | 1.54x | 53.73x |
| 2018 | $539.12 Million | $1.38 Billion | $38.79 Million | 0.39x | 13.90x |
| 2019 | $713.60 Million | $1.46 Billion | $42.07 Million | 0.49x | 16.96x |
| 2020 | $801.85 Million | $1.32 Billion | $94.62 Million | 0.61x | 8.47x |
| 2021 | $816.40 Million | $1.56 Billion | $130.40 Million | 0.52x | 6.26x |
| 2022 | $724.71 Million | $1.62 Billion | $180.78 Million | 0.45x | 4.01x |
| 2023 | $725.04 Million | $1.64 Billion | $188.06 Million | 0.44x | 3.86x |
| 2024 | $608.94 Million | $1.35 Billion | -$1.37 Billion | 0.45x | N/A |
Competitor Companies of 300110 by Market Capitalization
Companies near Huaren Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Huaren Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Huaren Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Huaren Pharmaceutical Co Ltd's market cap moved from $1.36 Billion to $ 544.93 Million, with a yearly change of -5.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥544.93 Million | 0.00% |
| 2025 | CN¥544.93 Million | -10.51% |
| 2024 | CN¥608.94 Million | -16.01% |
| 2023 | CN¥725.04 Million | +0.05% |
| 2022 | CN¥724.71 Million | -11.23% |
| 2021 | CN¥816.40 Million | +1.81% |
| 2020 | CN¥801.85 Million | +12.37% |
| 2019 | CN¥713.60 Million | +32.36% |
| 2018 | CN¥539.12 Million | -73.27% |
| 2017 | CN¥2.02 Billion | +34.51% |
| 2016 | CN¥1.50 Billion | +10.28% |
| 2015 | CN¥1.36 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Huaren Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $544.93 Million USD |
| MoneyControl | $544.93 Million USD |
| MarketWatch | $544.93 Million USD |
| marketcap.company | $544.93 Million USD |
| Reuters | $544.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Huaren Pharmaceutical Co Ltd
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therape… Read more